Full Press Release Details
INmune Bio Announces Allowance of U.S. Patent Covering Method
for Treating Cancer by In Vivo Priming of Natural Killer Cells
LA JOLLA, Calif., April 22,
2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness
the patient's innate immune system to fight disease, announced today that the United States Patent and Trademark Office
(USPTO) has given formal notice of allowance in patent application serial no. 15/268,399, titled "IN VIVO PRIMING OF NATURAL
KILLER CELLS," which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation
and contacting a patient's own natural killer cells within the body to induce an in vivo response, namely, the priming
of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient.
The newly allowed patent is
expected to issue within ninety days and will be set to expire in 2036, subject to patent term adjustment or extension.
"This patent application
was submitted at the genesis of the INKmuneTM program and evidences the novel thinking and innovation demonstrated
by INmune's founders," said Joshua Schoonover, Assoc. General Counsel of INmune Bio. "We expect to leverage
the USPTO's indication of allowable subject matter in global patent application counterparts, which we believe will expedite
patent allowance in several key jurisdictions outside the US. This forthcoming patent enhances the Company's IP portfolio,
and serves as a foundational asset for the INKmuneTM program."
INmune Bio Chief Scientific
Officer, Mark Lowdell, Ph.D. added: "This is a real landmark for the Company as it represents the first patent of technology
arising from the Company's founders. It cements our position as one of the only companies with an NK activating cell line
suitable for direct injection into patients that we are aware of. The patent allowance is perfectly timed as we move forward into
the clinic with INKmuneTM in two indications this year." INB16 is a proprietary cell line owned by INmune Bio
and has demonstrated capability to prime NK cells in controlled experiments, whereas INKmuneTM is a commercialized
embodiment of the INB16 cell line that is inactivated and prepared as a therapeutic agent for use in treating cancer. "I
am particularly excited by the patent allowance as it protects and encourages INB16 and our INKmuneTM platform,"
The Company expects to continue
innovation and patent portfolio building as it develops its clinical programs.
In the absence of all of the
required activating signals, a patient's natural killer cells ("NK cells") cannot effectively recognize and
kill cancer cells. INKmuneTM, is a biologic delivery system that allows for the delivery of essential priming signals
to patients' resting NK cells. INKmune is formulated for easy local storage in hospital pharmacies and delivered
by routine IV infusion. Once in the patient's body, INKmune comes in contact with resting NK cells. The
interaction converts NK cells to "primed NK cells" similar to an "on-off" switch. Primed NK cells
then remain primed until they contact and kill cancer cells.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly
traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently
being developed for COVID-19 complications (DN-TNF), cancer (INB03 ), Alzheimer's (XPro595), and NASH (LIVNate ).
The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal
residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit
Forward Looking Statements
Any statements contained in
this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations
but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 ,
XPro1595, LIVNate and INKmune are still in clinical trials and have not been approved and there cannot be any assurance that they
will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot
be any assurance of the success of this trial. The factors that could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more
drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to
conduct research and development, clinical studies and future product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified
and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's
Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form
8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance
that may arise after the date of this release.